Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Status: Enrolling
Updated:  6/4/2013
Clinical Research Facility
mi
from
Houston, TX
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Status: Enrolling
Updated: 6/4/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Status: Enrolling
Updated:  6/4/2013
Clinical Research Facility
mi
from
Annandale, VA
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Status: Enrolling
Updated: 6/4/2013
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Status: Enrolling
Updated:  6/4/2013
Clinical Research Facility
mi
from
Bellingham, WA
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Status: Enrolling
Updated: 6/4/2013
Clinical Research Facility
mi
from
Bellingham, WA
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Florida Academic Dermatology Centers
mi
from
Miami, FL
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Florida Academic Dermatology Centers
mi
from
Miami, FL
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Emroy University
mi
from
Atlanta, GA
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Emroy University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Rush University
mi
from
Chicago, IL
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Rush University
mi
from
Chicago, IL
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Tulane
mi
from
New Orleans, LA
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Tulane
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Michigan
mi
from
Ann Arbor, MI
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Minnesota Medical School
mi
from
Minneapolis, MN
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Minnesota Medical School
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Washington University
mi
from
St. Louis, MO
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Rochester
mi
from
Rochester, NY
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Duke University
mi
from
Durham, NC
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Wake Forest University Health
mi
from
Winston-Salem, NC
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Wake Forest University Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Pittsburgh
mi
from
Pittsburgh, PA
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Vanderbilt
mi
from
Nashville, TN
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  6/11/2013
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 6/11/2013
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287
Status: Enrolling
Updated:  6/11/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287
Status: Enrolling
Updated: 6/11/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  6/12/2013
Clinical Research Facility
mi
from
Santa Clara, CA
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 6/12/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  6/12/2013
Clinical Research Facility
mi
from
St. Joseph, MO
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 6/12/2013
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Status: Enrolling
Updated:  6/16/2013
Florida Hospital, Center for Colon & Rectal Surgery
mi
from
Atlamonte Springs, FL
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Status: Enrolling
Updated: 6/16/2013
Florida Hospital, Center for Colon & Rectal Surgery
mi
from
Atlamonte Springs, FL
Click here to add this to my saved trials
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Status: Enrolling
Updated:  6/16/2013
18308 Murdock Circle, Suite 108
mi
from
Port Charlotte, FL
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Status: Enrolling
Updated: 6/16/2013
18308 Murdock Circle, Suite 108
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Status: Enrolling
Updated:  6/16/2013
CoxHealth Hospital, Colorectal Department
mi
from
Springfield, MO
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Status: Enrolling
Updated: 6/16/2013
CoxHealth Hospital, Colorectal Department
mi
from
Springfield, MO
Click here to add this to my saved trials
A Phase II Study of Umbilical Cord Blood Transplantation
A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
Status: Enrolling
Updated:  7/10/2013
Tufts Medical Center
mi
from
Boston, MA
A Phase II Study of Umbilical Cord Blood Transplantation
A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
Status: Enrolling
Updated: 7/10/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974 AM1)
A Phase 1b Trial of Dinaciclib in Combination With Rituximab in Subjects With Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Neptune, NJ
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974 AM1)
A Phase 1b Trial of Dinaciclib in Combination With Rituximab in Subjects With Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Neptune, NJ
Click here to add this to my saved trials
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL)
Status: Enrolling
Updated:  8/21/2013
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL)
Status: Enrolling
Updated: 8/21/2013
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Status: Enrolling
Updated:  11/22/2013
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Status: Enrolling
Updated: 11/22/2013
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Status: Enrolling
Updated:  11/22/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Status: Enrolling
Updated: 11/22/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  11/27/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 11/27/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease
Status: Enrolling
Updated:  12/3/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease
Status: Enrolling
Updated: 12/3/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Adequacy of Peripheral Blood Stem Cell Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine: A Pilot Project and a Proof of Concept Study
Status: Enrolling
Updated:  12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Adequacy of Peripheral Blood Stem Cell Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine: A Pilot Project and a Proof of Concept Study
Status: Enrolling
Updated: 12/30/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase I Study of Milatuzumab for Graft Versus Host Disease
A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  1/22/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Phase I Study of Milatuzumab for Graft Versus Host Disease
A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 1/22/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
UCLA Division of Hematology-Oncology
mi
from
Los Angeles, CA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
UCLA Division of Hematology-Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Mayo Clinic
mi
from
Jacksonville, FL
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
University of Kansas Cancer Center and Medical Center
mi
from
Westwood, KA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
University of Kansas Cancer Center and Medical Center
mi
from
Westwood, KA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
B. Douglas Smith, M.D.
mi
from
Baltimore, MD
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
B. Douglas Smith, M.D.
mi
from
Baltimore, MD
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated:  1/23/2014
University of Washington School of Medicine
mi
from
Seattle, WA
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
Status: Enrolling
Updated: 1/23/2014
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199
Status: Enrolling
Updated:  2/26/2014
Clinical Research Facility
mi
from
Hackensack, NJ
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199
Status: Enrolling
Updated: 2/26/2014
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Gainesville, FL
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/31/2014
Pfizer Investigational Site
mi
from
Philadelphia, PA
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/31/2014
Pfizer Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials